David Kelly
Chairman
Iterum Therapeutics plc (ITRMF)Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
About David Kelly
David Kelly is recorded as Chairman at Iterum Therapeutics plc (ITRMF). Iterum Therapeutics plc reported in an 8-K filed March 10, 2025 that David Kelly was appointed Chairman of the Board, effective March 10, 2025.
“On March 7, 2025, the Board also appointed David Kelly, an existing director of the Board, as Chairman of the Board, effective as of March 10, 2025, following the resignation of the former Chairman, Ronald M. Hunt, as director of the Board on February 14, 2025.”
Summary generated from SEC filings and earnings-call records held by Equibles.
Affiliation history
Recorded current and former roles; source labels appear when available.
-
Current
2025-03-10–present
Company network
Recorded roles and call appearances connecting this person to public companies.
Leadership on record at Iterum Therapeutics plc
Other people whose current roles at this company are on record from its filings.
- Brenton K. Ahrens Chairman
- Beth Hecht Board Member
- Beth P. Hecht Board Member
- Corey Fishman Board Member
- David G. Kelly Board Member
- Joseph J. Whalen Board Member
- Michael Dunne, M.D. Board Member
- Michael W. Dunne Board Member
Recent activity
Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.